All In Biotech

NDA 212320 · Shield Tx

Accrufer

Ferric Maltol · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 25, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

8 Phase 3, 1 recruiting

FAERS reports

1,060

214 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 2, 2026.

ACCRUFER is indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older. ACCRUFER is an iron replacement product indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2025 Supplement 19 · Efficacy · priority review LabelLetter
  • Jul 25, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • ACCRUFER · FERRIC MALTOL 30MG IRON · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ferric Maltol" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • constipation160
  • inappropriate schedule of product administration108
  • abdominal discomfort104
  • diarrhoea103
  • nausea99
  • abdominal pain upper75
  • maternal exposure during pregnancy71
  • treatment noncompliance61
  • drug ineffective51
  • off label use42
  • death39
  • vomiting34

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20182
20192
20203
20217
202235
202393
2024272
2025576
202669

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Shield Tx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.